SyntheticMR AB has developed a proprietary analytical and visualization tools enabling synthetic MRI which help clinicians to reduce the time needed for MR-imaging dramatically, thereby increasing patient throughput. Synthetic MR synthesizes all possible MRI parameters from a simple general scan, eliminating the extra time needed to perform multiple scans. Other advantages of synthetic MR are improved performance from current image analysis systems and the possibility to analyze fewer but more precise images.
AddBIO AB develops and commercializes products for local drug delivery, improving the performance of implants. Primary development focus is on an implant coating for dental and orthopedic implants, called Zolidd®. Zolidd provides local delivery of a bone strengthening drug, and so increases the stability of the implant and enhances the holding power of the bone. It can thereby reduce the risk of complications and revision rates of bone implants, thus reducing healthcare expenses by improving functionality and extending the life time of bone implants.
Optovent AB/Archaea Pharma AB
Optovent AB develops and commercializes research based innovations within drug delivery. The primary development project is carried out within Optovent’s subsidiary, Archaea Pharma. Archaea Pharma is developing a drug delivery platform for targeted and local delivery of cytotoxic drugs directly to the tumor site. This has the potential to both improve treatment effectiveness as well as reduce unwanted side effects.
OptoQ AB is a medical device company that markets and sells technology platforms for safe and cost effective patient-monitoring. The company has developed a light based fibre-optic patient monitoring technique focusing on non-invasive measurement of haemoglobin and other physiological parameters for medical diagnostics.